Abstract:Background Polyethylene glycol (PEG) is a non-protein polymer that is present in its native (unbound) form as an excipient in a range of products, and is increasingly being utilised clinically in the form of PEGylated liposomal medications and vaccines. PEG is the cause of anaphylaxis in a small percentage of drug reactions, however diagnosis of PEG allergy is complicated by the variable and poor diagnostic performance of current skin testing protocols. Objective We assessed the diagnostic performance of PEGylated lipid medications as an alternative to currently described tests that use medications containing PEG excipients. Methods Nine patients with a strong history of PEG allergy were evaluated by skin testing with a panel of PEG-containing medications, and with a PEGylated lipid nanoparticle vaccine (BNT162b2). Reactivity of basophils to unbound and liposomal PEG was assessed ex vivo, and specificity of basophil responses to PEGylated liposomes was investigated with a competitive inhibition assay. For detailed Methods, please see the Methods section in this article's Online Repository. Results Despite compelling histories of anaphylaxis to PEG-containing medications, only two out of nine patients (22%) returned a positive skin test to purified PEG or their index-reaction indicated PEG-containing compound. Conversely, nine out of nine patients (100%) were skin test positive or basophil activation test positive to PEGylated liposomal BNT162b2 vaccine. Concordantly, PEGylated liposomal drugs (BNT162b2 vaccine and PEGylated liposomal doxorubicin), but not purified PEG2000, consistently induced basophil activation ex vivo in patients with PEG allergy but not in non-allergic controls. Basophil reactivity to PEGylated nanoparticles competitively inhibited by pre-incubation of basophils with native PEG2000. Conclusion We demonstrate that presentation of PEG on the surface of a lipid nanoparticle increases its in vivo and ex vivo allergenicity, and improves diagnosis of PEG allergy.

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Anti-PEG Antibodies: Current Situation and Countermeasures

Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies

Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy

Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum

Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated-Granulocyte Colony-Stimulating Factor

An Assay for Immunogenic Detection of Anti‐PEG Antibody

PEGylated Liposomes for Diagnosis of Polyethylene Glycol Allergy

Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers

Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin

A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Hydroxy polyethylene glycol: a solution to evade human pre-existing anti-PEG antibodies for efficient delivery

Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine

Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice

Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study

The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes

Complement activation-related pseudo allergy of PEGylated products: Safety aspects, models, the role of anti-PEG antibodies, and ways to overcome

Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering